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Abstract
Introduction:Our aimwas to study whether systemic metabolites are associated with
magnetic resonance imaging (MRI) measures of brain and hippocampal atrophy and
white matter hyperintensities (WMH).
Methods: We studied associations of 143 plasma-based metabolites with MRI mea-
sures of brain and hippocampal atrophy and WMH in three independent cohorts
(n = 3962). We meta-analyzed the results of linear regression analyses to determine
the association of metabolites withMRImeasures.
Results: Higher glucose levels and lower levels of three small high density lipoprotein
(HDL) particles were associated with brain atrophy. Higher glucose levels were associ-
ated withWMH.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and nomodifications or adaptations aremade.
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Discussion: Glucose levels were associated with brain atrophy and WMH, and small
HDL particle levels were associated with brain atrophy. Circulating metabolites may
aid in developing future intervention trials.
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1 BACKGROUND
Dementia, including Alzheimer’s disease (AD), is a rapidly growing
health care problem. Vascular disease is an important contributor
to AD pathology.1 Moreover, adequate treatment of cardiovascular
risk factors has been associated with a reduced risk of dementia.2
Low density lipoprotein cholesterol (LDL) is an important risk factor
for cardiovascular disease, and lowering LDL improves cardiovascu-
lar outcomes.3 This has fueled research on metabolic factors that are
potentially involved in the etiology of AD. Brain atrophy, hippocam-
pal atrophy, and white matter hyperintensities (WMH) measured on
magnetic resonance imaging (MRI) are neurodegenerative and vascu-
lar imagingmarkers characteristic of AD.4–6 Detailed understanding of
metabolic factors related to imagingmarkers of AD can provide insight
into biological pathways.
Metabolic processes can be investigated currently by large high
throughput platforms for simultaneous analysis of many metabolites.7
Previous studies highlight that altered lipid metabolism and decreased
levels of amino acids are associated with cognitive decline and
dementia.8,9 Moreover, in a recent multicenter study, we found 15
metabolites associated with cognitive function including higher high-
density lipoprotein (HDL) subclasses and docosahexaenoic acid and
lower ornithine, glutamine, and glycoprotein acetyls.10 These stud-
ies, however, only associated metabolite concentrations with clini-
cal signs and symptoms. To study possible underlying mechanisms
of metabolic dysregulation in AD, studies should include biolog-
ical measures, such as brain MRI features of brain atrophy and
WMH.
We aimed to investigate the association between blood-
based metabolites and global brain atrophy, hippocampal atro-
phy, and WMH across the clinical spectrum of AD in almost
4000 participants from three different Dutch cohort studies, a
memory-clinic study, a population-based study, and a family-based
study.
2 METHODS
2.1 Cohort description
The study population included 3962 participants from three prospec-
tive cohort studies; the memory-clinic–based Amsterdam Demen-
tia Cohort (ADC; n = 980), the population-based Rotterdam Study
(n= 2918), and the family-based Erasmus Rucphen Family (ERF) Study
(n = 64). All studies were part of the BioBanking for Medical Research
Infrastructure of the Netherlands (BBMRI) metabolomics consortium.
Participants were included if they underwent brain MRI and metabo-
lite data were available. In addition, in the ADC, participants were only
included with a clinical diagnosis of mild cognitive impairment (MCI)
(n = 130) or AD dementia (n = 523), and controls with subjective cog-
nitive decline (n = 327).11 In the Rotterdam Study (n = 2918) and ERF
Study (n = 64), participants were only included if they had no demen-
tia or stroke.12,13 All studies have been approved by a medical ethics
committee. All participants provided written informed consent to par-
ticipate in the study.
2.2 MRI measures
2.2.1 Amsterdam Dementia Cohort
MRI scans were obtained at 1.0, 1.5, or 3.0 T scanners. Details on scan-
ners and acquisition parameters can be found in Supplementary Table
1.
The scan protocol essentially remained the same over the years.
Visual ratings were performed by a trained rater and subsequently
evaluated in a consensus meeting together with an experienced
neuroradiologist.14,15 Global cortical atrophy (GCA) was visually
rated on axial fluid-attenuated inversion recovery sequence (FLAIR)
sequence images (range 0-3).16 Medial temporal lobe atrophy (MTA)
was ratedusing a five-point rating scale (0-4)17 on coronal T1-weighted
images; the mean of left and right MTA scores was used for data anal-
ysis. WMH were assessed on the FLAIR images using the Fazekas
scale, with scores from 0 to 3 (none, punctuate, early confluent, and
confluent).18 More information about the visual rating scales can be
found in Supplementary Table 2.
2.2.2 Rotterdam Study and Erasmus Rucphen
Family Study
Brain MRI scans were obtained with a 1.5-T scanner.19 Details on
scanners and acquisition parameters can be found in Supplementary
Table 1. Brain volume, graymatter volume,whitematter volume,WMH
volume, and intracranial volume (ICV) (in milliliters) were estimated
using automated segmentation using the FreeSurfer software.19 Total
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brain volume was defined as the sum of all voxels within the skull,
except cerebellum, brainstem, ventricles, cerebrospinal fluid (CSF), and
choroid plexus.20 Hippocampus volume was defined as the mean of
right and left hippocampal volumes.
2.3 Metabolites
Metabolites were quantified from non-fasted (in ADC) and fasted
(in Rotterdam Study and ERF Study) ethylenediaminetetraacetic
acid (EDTA) plasma samples using high-throughput proton nuclear
magnetic resonance metabolomics (Nightingale Ltd, Helsinki, Fin-
land).This metabolite platform enables simultaneous quantification of
231 lipoprotein subclasses and metabolites including amino acids,
ketone bodies, and gluconeogenesis-related metabolites.10,21,22 The
data set included 150 absolute metabolite measures. Six metabo-
lites with >10% missing in one of the cohorts were excluded from
data analysis. Pyruvate was excluded because this measurement
is not reliable in EDTA plasma.23 All included metabolites were
measured as concentrations ([m]mol/L or g/L), except for albumin
reported as signal area and three metabolite derivatives measur-
ing lipid particle volume in nanometer. The final data set included
143metabolites.
2.4 Covariates
In ADC, Rotterdam study, and ERF Study apolipoprotein E (APOE)
genotype was measured as described previously.24–26 Subjects were
classified as APOE ε4 carrier or non-carrier. Use of lipid-lowering med-
ication (yes/no) was assessed in all cohorts. Body mass index (BMI)
was calculated as kg/m2. In the ADC, 125 subjects (13%) missed BMI
measurement. Missing values were estimated by five times imputation
using the predictive mean matching method as implemented in the R
packageMICE.
2.5 Data pre-processing
All metabolites were transformed using natural logarithmic transfor-
mation (ln[x+1]), and next, both metabolites and MRI measures were
Z-transformed. For Z-transformationweused themean and SDof each
(sub)cohort in the Rotterdam Study and ERF Study. For the ADC Z-
transformation of metabolites and MRI measures was done by calcu-
lating SD units with controls as a reference group in order to increase
comparability of effectsbetweencohorts. For theRotterdamStudyand
ERF Study the measurement of brain MRI measurements was trans-
formed using ln(x+1) before Z-transformation. GCA and MTA were
inversed in such away that direction of visual scores in the ADC cohort
was the same as for WMH and the volumetric data in the Rotterdam
Study and ERF Study (ie, higher scores means less brain/hippocampal
atrophy ormoreWMH).
HIGHLIGHTS
∙ Multiple metabolites were related to brain atrophy and
white matter hyperintensities (WMH).
∙ Thesemetabolites are promising for further validation.
∙ Predominantly lower small high-density lipoprotein (HDL)
particle levels were associated withmore brain atrophy.
∙ Higher glucose levels were associated with more brain
atrophy andWMH.
∙ These metabolites might be of interest for future studies
exploring biological pathways in neurodegenerative dis-
eases, such as Alzheimer’s disease (AD).
RESEARCH INCONTEXT
1. Systematic review: Previous studies have discovered cir-
culating metabolites as determinants of cognitive func-
tion and dementia. However, underlying biological mech-
anisms between metabolites and Alzheimer’s disease
(AD) have not been studied. Examining the associations of
metaboliteswithbrainmagnetic resonance imaging (MRI)
measures characteristic of AD might provide a deeper
understanding of themetabolic determinants of AD.
2. Interpretation: In this multi-cohort study we found that
higher glucose levels were associated with brain atrophy
andWMH, and lower small HDLparticle levelswere asso-
ciated with brain atrophy.
3. Future directions: Our findings have emphasized that cir-
culating metabolites are related to neurodegenerative
and neurovascular brain changes that are characteristic
for AD. Future studies should be performed to validate
ourmetabolite findings and indicate if metabolites can be
used as treatment targets or to stratify patients for inter-
vention trials.
2.6 Statistical analyses
All analyses were performed in R (version 3.5.2 [2018-07-02]). Cohort
differences in participant characteristics were tested using one-way
analysis of variance with post-hoc Bonferroni adjusted t tests for
continuous variables or χ2 tests for categorical variables. Linear
regression analyses were used to assess the association of each of the
143 metabolites with brain atrophy, hippocampal atrophy, and WMH
in separate models. All associations were assessed in two models: a
first model, adjusted for age and sex. In the Rotterdam Study and ERF
Study the first model was additionally adjusted for ICV. In model 2,
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TABLE 1 Characteristics of the study population by cohort
Cohort ADC Rotterdam Study ERF Study P-value
N 980 2918 64
Age, years 64± 9 69± 9
a
64± 4
b
<0.001
Female 449 (46) 1664 (57)
a
35 (55) <0.001
Diagnosis Controls 327 (33)MCI 130
(13) AD dementia 523 (53)
No dementia 2918 (100) No dementia 64 (100) N/A
APOE ε4 carrier 519 (54) 762 (27)a 23 (40)a <0.001
Lipid-loweringmedication 209 (21) 745 (25)a 16 (25) 0.03
Time difference scan date and date blood
withdrawal, years
0.0± 0.0 2.0± 3.4
a
3.7± 0.7
a,b
<0.001
Stroke 24 (2) 0 (0) 0 (0) N/A
MRI
GCA scale 0 (0-1)
MTA scale 1 (0-1.5)
Fazekas scale 1 (0-1)
Intracranial volume, mm3 1,469,849
(1,366,670-1,584,694)
1,419,618
(1,291,443-1,544,271)
Total brain volume, mm3 889,950
(826,270-959,679)
878,054
(815,299-958,440)
Hippocampal volume, mm3 3,852 (3,544-4,131) 3,810 (3,524-4,155)
Whitematter hyperintensity volume, mm3 1,952 (1,282-3,405) 1,710 (1,005-2,854)
Data are presented as mean ± SD, median (interquartile range) or n (%). Differences were tested with one-way analysis of variance (ANOVA) with post hoc
Bonferroni adjusted t tests for continuous variables andwith chi-square tests for categorical variables. Significant difference upon post hoc testing to
a
ADC
b
Rotterdam Study.
Abbreviations:AD,Alzheimer’s disease;ADC,AmsterdamDementiaCohort;APOE, apolipoproteinEgene; ERF, ErasmusRucphenFamily;GCA, global cortical
atrophy;MCI, mild cognitive impairment;MMSE, mini-mental state examination;MTA, medial temporal atrophy; N/A, not applicable; SD, standard deviation.
we adjusted for age, sex, ICV (Rotterdam Study and ERF Study), use
of lipid lowering medication, BMI, and APOE ε4 presence. For model
2 with adjustment for (imputed) BMI values in the ADC, results were
pooled over imputed data sets using Rubin rules as implemented
in the R package MICE.27 Effect estimates of the linear regression
analyses by cohorts (ADC, threeRotterdamStudy subcohorts and, ERF
Study) were combined with inverse variance-weighted fixed-effects
meta-analysis using the “rmeta” package (version 3.0). In addition, we
present three sensitivity analysis: (1) excluding subjects with a clinical
AD dementia diagnosis, (2) stratified for a diagnosis of diabetes mel-
litus (DM) (yes/no), and (3) stratified for a short (≤6 months) and long
(>6 months) time interval between blood sampling and MRI. Because
metabolites are highly correlated we used the method of Li and Ji (4)
to correct for multiple testing using R (version 3.5.2 [2018-07-02]) and
the R package “Hmisc”. With this method, we calculated the “effective
number”’ (Meff) of independent tests. The full formulas are explained
in detail by Li and Ji (4). In our study, 143 metabolites corresponded to
27 independent tests (P for significance= 0.05/27= 1.85 × 10−3). The
association magnitudes are reported in units of SD per 1 SD increase
in each metabolite. We used METAL (version 2011-03-25) to check
whether heterogeneity plays a role in the variation in results between
our different studies by calculating the Iš statistic. A heatmapwas used
to visualize the distribution of effects found between each metabolite
andMRImeasures using the “heatmap.2″ R package.
3 RESULTS
3.1 Descriptives
Characteristics of each cohort and diagnosis group are presented in
Table 1. The Rotterdam Study included more females and older sub-
jects than those in the ERF Study and the ADC. The proportion APOE
ε4 carriers was highest in the ADC and lowest in the Rotterdam Study.
3.2 Metabolic patterns of neurodegeneration and
vascular brain changes
Figure 1 shows a heatmap of all associations of metabolites with MRI
measurements (model 2). Although only a limited number of associa-
tions pass the threshold for significance (as reported in 3.3 and 3.4)
some global patterns can be observed. Overall, lower levels of LDL
cholesterol particles andhigher levels of triglycerides andglucosewere
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F IGURE 1 Associations of metabolites withMRImeasures. Colors represent the standardized effect estimates of metabolites with brain
volume, hippocampus volume, andwhite matter hyperintensities (WMH) adjusted for sex, age, lipid-loweringmedication, bodymass index, and
apolipoprotein ε4 status. Red, high; blue, low; white, in between. * Stands for P-value< 0.05 and ** stands for P-value below the threshold for
multiple testing P< 1.85× 10−3. Abbreviations: HDL, high density lipoprotein; (V)LDL, (very) low density lipoprotein;WMH, white matter
hyperintensities
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F IGURE 2 Associations of metabolites with brain volume. The standardized effect estimates of metabolites on brain volume adjusted for sex,
age, lipid-loweringmedication, bodymass index, and apolipoprotein ε4 status are shown. Point estimates are shown as boxes with whiskers
denoting the 95% confidence interval of the effect estimates. Abbreviations: HDL, high density lipoprotein; SD, standard deviation
associated with more brain and hippocampal atrophy and moreWMH.
Moreover, higher levels of very-low-density lipoprotein particles were
associated with more hippocampal atrophy and more WMH. More
brain and hippocampal atrophy was additionally associated with lower
small HDL particles and higher citrate levels. Finally, more hippocam-
pal atrophy was associated with lower histidine, leucine, and valine
levels. Together this suggests some overlapping and some separate
metabolic patterns associated with neurodegenerative and vascular
brain changes.
3.3 Brain atrophy and hippocampal atrophy
In the meta-analysis for model 1, four metabolites passed
the threshold for significance for brain atrophy. Higher
glucose levels and lower total cholesterol in small HDL,
cholesterol esters in small HDL, and total lipids in small HDL levels
were associated with more brain atrophy (B[SE] −0.030[0.008],
P = 1.4 × 10−4, 0.031[0.008], P = 4.9 × 10−5, 0.028[0.008],
P = 2.6 × 10−4, 0.025[0.008], P = 1.4 × 10−3). In model 2 these
associations remained significant, except for the association between
total lipids in small HDL (Figure 2). The associations of higher glucose
levels and lower total cholesterol in small HDL and lower cholesterol
esters in small HDL with brain atrophy also surpassed the more strin-
gentBonferroni correction for significance (P=0.05/143<3.5×10−4).
In separate analyses of ADC and meta-analyses of Rotterdam Study
and ERF Study, direction of effects was the same as in the meta-
analyses for the three metabolites associated with brain atrophy
(Supplementary Table 3). No associations between metabolites and
hippocampus atrophy passed the threshold for multiple testing. An
exploratory analysis in the MCI and AD group (n = 653) showed no
associations between metabolites and hippocampus atrophy that
surpassed the threshold for multiple testing either (data not shown).
3.4 White matter hyperintensities
In the meta-analysis for model 1, higher glucose and glycopro-
tein acetyls were associated with more WMH (B[SE] 0.071[0.015],
P= 1.5 × 10−6, 0.051[0.014], P= 4.0 × 10−4). In model 2, these effects
attenuated, and only effects for glucose remained significant (B[SE]
0.051 [0.016], P = 1.5 × 10−3). In separate analyses of ADC and meta-
analyses of Rotterdam Study and ERF Study, the same direction of
effects was found as in the meta-analyses for glucose (Supplementary
Table 3).
3.5 Heterogeneity of results
Next, heterogeneity analysis was used to assess the variety in results
between studies. I2 reflects the percentage of variation across stud-
ies due to heterogeneity (Supplementary Table 3). The association
between total cholesterol in small HDL and cholesterol esters in small
HDL and brain atrophy were consistent among the different studies,
with an I2 value of 21.8 (P = 2.8 × 10−1) and 2.9 (P = 3.9 × 10−1) in
model 2. For the association between glucose and brain atrophy and
WMH, the I2 was 41.1 (P= 1.5× 10−1) and 45.8 (P= 1.2× 10−1).
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3.6 Sensitivity analyses
We examined three sensitivity analyses to determine effects of: (1)
clinical AD dementia diagnosis, (2) DM, and (3) time interval between
blood sampling and brain MRI scanning. To determine whether the
observed effects may be driven by disease effects of AD dementia,
we reanalyzed the data excluding the subjects with a clinical diag-
nosis of AD dementia (n = 523, ADC). In model 2, the associations
between total cholesterol in smallHDL, cholesterol esters in smallHDL
levels, and glucose with brain atrophy remained similar; the associa-
tion between glucose and WMH showed a similar effect size as in the
total cohort but lost significance (B[SE] 0.051 [0.017], P = 2.0 × 10−3)
(Supplementary Table 4). Next, we hypothesized that the association
of higher glucose levels with more brain atrophy and more WMH
might be different for subjects with DM (n = 373) and those with-
out DM (n = 3552). For the association of glucose with brain atro-
phy, effect sizes diminished and became non-significant in both sub-
groups (B[SE] −0.023[0.030], P = 4.4 × 10−1 DM, −0.020[0.009],
P = 2.1 × 10−2 no DM, model 2). Effect sizes for the association
of glucose with WMH were substantially larger in the DM subgroup
(B[SE] 0.136[0.057], P = 1.7 × 10−2) versus the subgroup without DM
(B[SE] 0.023[0.017], P = 1.7 × 10−1, model 2) (Supplementary Tables
5 and 6). Furthermore, we performed stratified analyses based on the
time difference between bloodwithdrawal and brainMRI scanning (≤6
months [n = 2432] vs >6 months [n = 1530]) (Supplementary Tables 7
and 8). Lower total cholesterol in small HDL and cholesterol esters in
small HDL levels remained associated with more brain atrophy in the
subgroup with a short time interval (≤6 months) (B[SE] 0.041[0.011],
P = 2.2 × 10−4, 0.037[0.011], P = 5.8 × 10−4), but effect sizes were
smaller and lost significance in the long time interval group (>6months)
(B[SE] 0.026[0.012], P = 3.6 × 10−2, 0.016[0.012], P = 2.0 × 10−1,
model 2). The association of high glucose levels with more brain atro-
phy and more WMH was slightly weaker in the subgroup with a
short time interval (≤6 months) (B[SE] -0.028[0.012], P = 2.0 × 10−2,
0.044[0.021], P = 3.8 × 10−2), in comparison to the long time interval
group (>6months) (B[SE]−0.045[0.013], P= 2.8× 10−4, 0.058[0.025],
P= 2.0× 10−2).
4 DISCUSSION
In this multi-cohort study, lower levels of small HDL particles were
associated with more brain atrophy. In addition, high glucose levels
were associated withmore brain atrophy andmoreWMH.
The present study suggests a harmful role of high glucose levels
on brain atrophy and vasculature. DM has been associated with an
increased risk of cognitive decline and dementia.28 Sensitivity analy-
ses showed that the association of glucose withWMHmight be largely
attributable to DM subjects, but our findings with brain atrophy were
not specific for DM, suggesting that higher glucose levels might also
be harmful in subjects without DM. Previous work in the Rotterdam
Study shows that higher baseline insulin resistance is associated with
an increased risk ofAD.29 Recent studies also link systemic glucose lev-
els with brain measures, showing that higher blood glucose levels are
associated with aberrant functional brain connectivity,WMH, and cor-
tical thinning in healthy subjects.30–32 Glucose dysregulation and DM
are strongly associated with diet and lifestyle. TheMediterranean diet
has shown beneficial effects on DM risk, cognition, brain volumes, and
WMH.33–35 These studies are consistent with our findings and under-
score the potential for lifestyle interventions in the prevention of AD.
Lower levels of small HDLparticleswere associatedwithmore brain
atrophy. In a previous study investigating the role of HDL subclasses
on cognition and dementia risk, we found that higher levels of small,
medium, and largeHDLparticleswere associatedwith better cognitive
ability, and that only higher levels of small and medium HDL particles
were associated with decreased risk of dementia.10 This in line with
our findings, and together our studies suggest that the smaller HDL
particles might be more specific for neurodegeneration. Protective
effects of high levels of HDL are thought to rely on the promoting
effects of HDL on the reverse cholesterol transport. The current
knowledge on HDL subclasses is limited, but previous studies suggest
that subclasses differ in function and ability to promote cholesterol
efflux.36–38 For example, small HDL has been suggested to have
more anti-oxidant and anti-inflammatory properties in comparison
to lipid-rich large HDL.39 This could explain the association we found
for higher levels of small HDL with less brain atrophy. Perhaps the
anti-oxidative and anti-inflammatory properties of small HDL protect
the brain for neurodegenerative brain damage. In our study, levels
of total HDL as measured in clinical practice showed no associations
with brain atrophy or hippocampal atrophy (B[SE] -0.006 [0.009],
P = 5.2 × 10−1 for brain atrophy, B[SE] 0.006 [0.017] P = 7.2 × 10−1
for hippocampal atrophy, model 2) suggesting that HDL subclasses
are more informative when studying the role of HDL in neurode-
generation. Furthermore, HDL has been studied widely in relation
to cardiovascular disease, which is also an important risk factor for
AD.40,36 Considering the beneficial effect of HDL on vascular disease
we might have expected an association between HDL and WMH
instead of brain atrophy. Previous studies examining the role of HDL
subclasses on cardiovascular outcomes, however, found that smallHDL
particles predict higher risk on cardiovascular disease and that large
HDL particles are protective for cardiovascular disease.38,41 This is in
contrast with our findings for low small HDL particle levels associated
with more brain atrophy, suggesting that the effects of small HDL we
found might not be mediated by vascular pathology but might depend
onother the anti-oxidative, anti-inflammatory properties of smallHDL.
We did not find any significant associations between metabo-
lites and hippocampal atrophy. Hippocampal atrophy is a more AD-
specific measure of neurodegeneration in comparison to global brain
atrophy.42 Only the ADC included AD dementia patients, which could
have caused insufficient power to detect significant associations with
hippocampal atrophy. In themeta-analysis, strongest associationswith
more hippocampal atrophy were found for lower small HDL particles,
histidine, leucine, and valine levels, andhigher citrate levels. This is con-
sistent with previous studies that have associated small HDL particles
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and branched-chain amino acids with lower dementia risk.9,10 More-
over, the finding for small HDL particles overlaps with the associa-
tionswe foundbetween lower small HDLparticle levels andmore brain
atrophy. Together, although our findings for hippocampus atrophy are
not significant, it might be interesting to further investigatemetabolite
associations with hippocampal atrophy in cohorts with larger number
of AD cases.
The associations betweenmetabolites andbrainmeasureswe found
in this study do indicate subtle effects with the moderate P-values.
This is a common observation when studying associations between
peripheral metabolites and brain diseases. AD is a multifactorial dis-
ease, and associations between peripheral metabolism and AD are
likely to involve multiple metabolic pathways. Therefore, one should
not strive to find strong single metabolic markers for clinical pur-
poses, but subtle metabolic patterns can provide us valuable insight
into the biological mechanisms for AD, as shown in our heatmap in
Figure 1.
A potential limitation of our study is that different methods were
used to estimate brain changes (volumetric in Rotterdam Study and
ERF Study; and visual rating in ADC). Because visual ratings are very
useful in daily clinical practice these were available for participants
from the ADC, which is a memory-clinic cohort. Moreover, ADC
participants were scanned on different scanners, which is a disadvan-
tage for volumetric measures, whereas visual ratings can be reliably
applied to different magnetic field strengths and scanners.43 Previous
studies have shown a similar validity of visual ratings and volumetric
measures.44,45 With transformation and standardization of our data,
we made the measured outcomes of interest comparable between
the different cohorts. Furthermore, our findings were robust, as the
main findings show the same direction of effects in the separate
cohort analysis as in the meta-analysis, which further emphasizes
generalizability of the results. Another potential limitation is that the
time between MRI and blood sampling in the Rotterdam Study and
ERF Study varied from no time difference to multiple years. This might
havemitigated our results as is shown in our sensitivity analysis where
effects of small HDL particles were stronger in the subgroup with
short time differences (≤6 months) than those with long (>6 months)
time differences. Next, metabolites of the Rotterdam Study and ERF
Studyweremeasured in fasting plasma samples, whereas the ADC had
only non-fasting samples. This might have influenced (consistency of)
our results; however, direction of metabolites for the top candidates
was in the same direction in all cohorts. Moreover, although fasting
metabolite measurements are preferable, concentrations of amino
acids, cholesterol, and several other metabolites have been shown to
be relatively stable in non-fasting blood samples.46,47 We note that our
findings are difficult to interpret in terms of causality.Whether a found
association is a cause or consequence of changes in the MRI measures
cannotbe studiedwith the cross-sectional designof this study. Further-
more, longitudinal studies should unravel whether these metabolites
are related to disease etiology or are merely a consequence of disease.
We did show, however, in a sensitivity analysis that our main findings
were not driven by AD dementia subjects only. Finally, we used MRI
measures as imaging endophenotypes of AD to investigate metabolite
alterations in both cognitively healthy and memory-clinic patients.
Imaging markers have the advantage to be more closely linked to
pathologic effects in comparison to clinical outcomes and enable us
to discover specific metabolic associations with neurodegeneration
and vascular changes. MRI features are, however, not specific for AD
and also associated with many other neurodegenerative diseases and
aging.48
Among the strengths of this study is our large sample size and direct
validation of our findings in three independent cohorts. Moreover, we
investigated associations ofmetaboliteswith neurodegenerative imag-
ingmarkers across the entire cognitive spectrumofAD. Thismakes our
findings broadly applicable regardless of disease state. Furthermore,
the same metabolite platform was used across the three cohorts to
measuremetabolites.
In summary, in a meta-analysis of three independent cohort studies
we found that lower small HDL levels and higher glucose levels were
associatedwithmore brain atrophy and that higher glucose levelswere
associatedwithmoreWMH. Future studies are needed to pinpoint the
role of these metabolites in neurodegenerative brain changes charac-
teristic for AD.
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